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Abstract
Background: Despite the introduction of new insulin analogs, insulin pumps, and continuous glucose monitoring (CGM), young
children with type 1 diabetes mellitus (T1D) remain vulnerable to episodes of hypoglycemia because of their unpredictable eating
and activity patterns and high degree of insulin sensitivity. Caregivers and young children living with T1D learn to fear
hypoglycemia because it is uncomfortable, unpredictable, and dangerous. Up to 60% of caregivers of young children with T1D
report moderate to severe levels of fear of hypoglycemia, and caregiver fear of hypoglycemia relates to lower quality of life for
families and suboptimal child glycemic control. Yet, until recently, there have been no studies reporting on a targeted intervention
to treat caregiver fear of hypoglycemia in families of young children.
Objective: The aim of this project is to conduct a randomized clinical trial of an innovative, video-based telehealth intervention
to treat fear of hypoglycemia in caregivers of young children with T1D versus a relevant, age-appropriate attention control
intervention.
Methods: We created the Reducing Emotional Distress for Childhood Hypoglycemia in Parents (REDCHiP) intervention by
merging age-appropriate T1D education and behavioral parenting strategies with cognitive behavioral therapy strategies that are
effective for reducing fear and promoting adaptive coping. REDCHiP uses 10 video-based telehealth sessions that are a combination
of group and individual sessions. We will recruit up to 180 families of young children with T1D to participate in this clinical trial
from two pediatric diabetes clinics located in the midwestern and southern United States. Once families have been enrolled, we
will randomize caregivers based on child age (age 2-3 years or 4-5 years), child sex, and family CGM use to participate in the
REDCHiP or attention control intervention. Families will complete 3 assessment visits that coincide with study entry, end of
treatment, and 3-month posttreatment. At each assessment visit, we will collect questionnaire data from caregivers, accelerometry
data from caregivers and children, CGM data from children, and a blood sample to measure glycated hemoglobin levels from
children.
Results: Recruitment began in July 2019, and enrollment is ongoing. The first wave of intervention delivery began in December
2019. We anticipate completing enrollment in 2023. Final reporting of results will occur within 12 months of the primary
completion date.
Conclusions: If the REDCHiP intervention is efficacious, next steps will be to examine multiple implementation strategies to
determine how best to disseminate the intervention to pediatric diabetes clinics around the world.
Trial Registration: ClinicalTrials.gov NCT03914547; https://clinicaltrials.gov/ct2/show/NCT03914547
http://www.researchprotocols.org/2020/8/e17877/
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Introduction
Background
Type 1 diabetes mellitus (T1D) is a common pediatric chronic
condition characterized by the loss of natural insulin production
and inability to regulate blood glucose levels. Incidence rates
of T1D are increasing in children aged younger than 6 years
internationally [1], and data also demonstrate a 1.7% average
annual increase of new cases among children aged 5 to 9 years
in the United States specifically [2]. Achieving near-normal
glycemic control (glycated hemoglobin [HbA1c] <7.5%) early
in the course of T1D may reduce economic burden to the health
care system, and most importantly, can reduce the risk for later
T1D-related complications [3]. This goal, however, is difficult
for young children with T1D and their families to achieve as
only 20% of young children in the United States and 58% of
young children in Europe currently meet the HbA1c target of
<7.5% [4]. Managing T1D is particularly challenging in young
children because of their heightened insulin sensitivity,
unpredictable eating behaviors, inconsistent physical activity
levels, and limited communication skills [5], which lead to
extreme glycemic variations and severe hypoglycemic episodes
[6].
Hypoglycemia events, or low blood glucose levels, are an
immediate and dangerous complication of T1D [7]. Symptoms
of hypoglycemia may include headaches, dizziness, impaired
consciousness, irritability, weakness, sweating, racing pulse,
and, in extreme cases, seizure, coma, or death [8,9]. Prevalence
rates for severe hypoglycemia in young children with T1D are
2-fold higher than older children and adolescents and 3-fold
higher than adults [10]. Not surprisingly, it is common for
caregivers of young children with T1D to report elevated stress
and anxiety regarding the probability of their child experiencing
a hypoglycemia event [11]. Unfortunately, the introduction of
new technologies such as shorter and longer acting insulin
analogs, insulin pumps, and continuous glucose monitors
(CGMs) have not eliminated the occurrence of hypoglycemia
events in young children [11-13] or reduced caregiver fear of
hypoglycemia [11,14].
Up to 60% of caregivers of young children with T1D report fear
of hypoglycemia, which directly affects caregiver psychological
and emotional well-being [15]. Additionally, in young children
with T1D, caregivers may perceive hypoglycemia as
unpredictable, exacerbating their level of fear [16]. Building on
past research, we developed a theoretical model for caregiver
fear of hypoglycemia (Figure 1) which identifies child and
caregiver variables that may underlie caregiver fear of
hypoglycemia. For example, we have data suggesting that a
child’s T1D history, including past experience with
hypoglycemia, and a child’s sleeping behavior may relate to
http://www.researchprotocols.org/2020/8/e17877/
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caregiver fear of hypoglycemia [15,17,18]. In addition, in older
youth with T1D, there is evidence that child physical activity
levels relate to caregiver fear of hypoglycemia [19-22].
For caregiver variables, several studies suggest that T1D-related
distress, parenting stress, caregiver depressive and anxiety
symptoms, and decreased caregiver sleep may exacerbate their
perceptions of fear of hypoglycemia [23-27]. Our theoretical
model of caregiver fear of hypoglycemia then proposes that
greater caregiver fear of hypoglycemia relates to hypoglycemia
avoidance behaviors, including maintaining blood glucose levels
above the recommended range, treating blood glucose levels
that are within the target range, and delaying or reducing insulin
doses [16,28]. Our theoretical model of caregiver fear of
hypoglycemia suggests that when caregivers engage in more
hypoglycemia avoidance behaviors, these maladaptive coping
strategies lead to chronically higher blood glucose levels, more
glycemic variability, and increased risk for T1D-related
complications for children [29,30]. Thus, our model suggests
that caregiver fear of hypoglycemia may function as a barrier
to optimal glycemic control and should be a target of behavioral
interventions for families of young children with T1D.
In-person clinic visits have been a mainstay of behavioral
interventions for families of youth with T1D, but this approach
also presents logistical barriers (eg, travel, time, and cost). For
this reason, the use of technology-based delivery methods has
increased both in research and clinical settings. Access to mobile
technology and the internet is ubiquitous in the United States.
Current estimates suggest that 90% of American adults use the
internet, 81% own smartphones, and 73% have high-speed
internet access at home [31,32]. To date, most technology-based
T1D interventions have focused on T1D management in
adolescents and young adults versus families of young children,
and the interventions have used email and text message support
[33-35], websites and phone apps [36-44], and telephone
counseling or video-based telehealth [45-51]. Yet these
technology-based interventions suggest that it may be highly
feasible and efficacious to use technology to intervene in
families of youth with T1D. Moreover, using technology to
intervene may be more scalable than in-person clinic delivery
and enable behavioral interventions to reach a broader patient
population, including families living in rural and underserved
locations.
This study will fill an existing gap in the current T1D literature
by developing and testing a video-based telehealth intervention
to reduce caregiver fear of hypoglycemia in families of young
children. Reducing Emotional Distress for Childhood
Hypoglycemia in Parents (REDCHiP) uses a cognitive
behavioral framework, T1D education, and behavioral parenting
support to directly address caregiver fear of hypoglycemia and
reduce their reliance on maladaptive coping strategies (including
hypoglycemia avoidance behaviors) with the potential for
JMIR Res Protoc 2020 | vol. 9 | iss. 8 | e17877 | p. 2
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downstream positive effects on young children’s T1D
management and glycemic control. This paper outlines how we
intend to examine the effectiveness of REDCHiP in reducing
parenting stress and fear of hypoglycemia compared with an

attention control intervention in a randomized clinical trial and
obtain information about the intervention’s feasibility,
acceptability, and impact on child glycemic control.

Figure 1. Theoretical model of caregiver fear of hypoglycemia.

Objectives
The aims of this randomized clinical trial are to (1) evaluate
whether caregivers who receive the REDCHiP intervention
report reductions in parenting stress and fear of hypoglycemia
immediately posttreatment compared with caregivers who
receive the attention control intervention; (2) evaluate whether
children of caregivers who receive the REDCHiP intervention
have lower HbA1c and less glycemic variability posttreatment
compared with children of caregivers who receive the attention
control intervention; and (3) examine whether maintenance
reductions in parenting stress and caregiver fear of
hypoglycemia and child HbA1c occur 3 months’ posttreatment
for families receiving the REDCHiP intervention. Based on
preliminary data, our primary hypotheses are (1) caregivers who
receive REDCHiP will report reductions in parenting stress and
fear of hypoglycemia compared with caregivers who receive
the attention control intervention and (2) children of caregivers
who receive REDCHiP will achieve more optimal glycemic
control than children of caregivers who receive the attention
control intervention.

Methods
Development of the Reducing Emotional Distress for
Childhood Hypoglycemia in Parents Intervention
REDCHiP includes a cognitive behavioral framework based on
the conceptualization that caregiver fear of hypoglycemia is a
type of specific phobia. Individuals with specific phobias are

“fearful or anxious about or avoidant of circumscribed objects
or situations” and experience “fear, anxiety, or avoidance [that]
is almost always immediately induced by the phobic situation,
to a degree that it is persistent and out of proportion to the actual
risk posed” [52]. Cognitive behavioral therapy plus systematic
desensitization and exposures is a well-studied, evidence-based
treatment for specific phobias in adults and demonstrates
reductions in fear to a subclinical level in 90% of cases [53]. In
REDCHiP, caregivers learn to recognize and alter thoughts and
behaviors driven by fear of hypoglycemia and gain new
behavioral parenting strategies and coping strategies to help
them manage their fear. REDCHiP consists of 7 group and 3
individual sessions that are each 30 to 60 minutes in duration
(Table 1).
We previously pilot-tested REDCHiP using a video-based
telehealth approach. A total of 36 families completed the pilot
intervention with low attrition (ie, 14%), high attendance (ie,
94%), and high caregiver-reported satisfaction [54].
Qualitatively, caregivers reported positive increases in
knowledge, fear awareness, coping, and confidence and
satisfaction with the support they received and the new
behavioral parenting skills they learned from the REDCHiP
intervention [54]. Quantitatively, caregivers experienced
significant reductions in fear of hypoglycemia, parenting stress,
and T1D-related distress [55]. Moreover, REDCHiP
significantly reduced caregiver fear of hypoglycemia as
compared against a waitlist control group, thus establishing
preliminary efficacy for the REDCHiP intervention [55].

Table 1. Overview of the Reducing Emotional Distress for Childhood Hypoglycemia in Parents intervention.
Session No.

Format

Content

1-3, 5, 7, 9-10

Group

Hypoglycemia fear is a type of phobia and behavioral parent training, cognitive behavioral framework
(eg, cognitive and behavioral responses to fear) and adaptations, diabetes education (eg, managing blood
glucose levels and recognizing patterns in blood glucose)

4, 6, 8

Individual

Building a fear hierarchy and guided exposure, diabetes education (eg, recognizing your child’s symptoms
of high and low glucose), challenging nighttime fear, problem-solving type 1 diabetes mellitus challenges

http://www.researchprotocols.org/2020/8/e17877/
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Attention Control Development
We used two approaches to determine the content of our
attention control intervention. First, parents of young children
(ages 1 to 6 years) provided input by reviewing a list of potential
topics and rating each topic on a 3-point scale according to its
degree of relevance to them (not relevant, somewhat relevant,
or very relevant). We then selected the topics identified as very
relevant by the majority of caregivers. Second, we asked 5
experts in young child development and clinical psychology to

review our initial list of topics and the list of topics caregivers
provided and provide recommendations for additional
developmentally and age-appropriate topics. The final list of
sessions includes topics relevant to young children (eg,
developmental milestones, child health and safety, starting
school), positive parenting strategies, and early literacy;
caregivers do not learn about T1D-related topics. To
complement the REDCHiP format, the attention control
intervention consists of 7 group and 3 individual sessions that
are each 30 to 60 minutes in duration (Table 2).

Table 2. Overview of the attitude control intervention.
Session No.

Format

Content

1-3, 5, 7, 9-10

Group

Behavioral parent training, early childhood milestones and experiences, literacy, communication, learning
through play

4, 6, 8

Individual

Early childhood safety topics (eg, injury prevention, car seat safety), creating a learning environment, establishing childhood routines and structure

Design Considerations and Potential Challenges
We carefully designed the trial to reduce the impact of several
potential challenges. First, we anticipated a challenge in
recruiting an adequate sample because in very young children,
T1D occurs at a prevalence of 0.29 per 1000 patients [56].
Therefore, we designed a multisite trial, which should enable
us to adequately recruit our anticipated sample. Second, we
anticipated barriers related to family availability and scheduling.
To minimize this barrier, we designed the trial to deliver
treatments via telehealth and include an option for families to
complete study visits from home. Third, based on our pilot trial,
we anticipated that a few eligible families (<10%) might not
own a compatible device or have internet connectivity.
Therefore, we have the flexibility in our trial design to loan
web-enabled tablets to families. Fourth, we considered the
possibility that some families might not find the intervention
content or telehealth delivery favorable and will withdraw. To
minimize negative trial effects due to attrition, we plan to recruit
180 families, which allows for a 20% attrition rate.

Ethics and Dissemination
This is a multisite trial and follows National Institutes of Health
guidelines to establish and operate within a single institutional
review board (IRB) for final study monitoring. All research
personnel will complete certification in responsible conduct of
research, good clinical practice, and safe handling of biological
samples. To minimize risk for participating families, we will
inform all potential families of the purpose, procedures, and
amount of time required to participate in the trial. We will
minimize risk of breach of confidentiality by using a Health
Insurance
Portability
and
Accountability
Act
(HIPAA)-compliant telehealth platform and reviewing a group
confidentiality agreement at the first session. We will minimize
the risk of child pain or emotional discomfort when collecting
blood samples by allowing families to use their own lancet
and/or coordinating the sample collection to occur just after a
clinic-based finger stick. Finally, we will protect caregivers by
reviewing their responses on the study surveys within 24 hours
of completion and contacting those who report concerning levels
of depressive or anxiety symptoms to provide information on
http://www.researchprotocols.org/2020/8/e17877/
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treatment resources. The trial
ClinicalTrials.gov [NCT03914547].

was

registered

at

The REDCHiP intervention builds on our previous research
examining fear of hypoglycemia in caregivers of young children
with T1D and fills a critical gap in behavioral intervention
research in these understudied families. Moreover, the
group-based telehealth approach is relatively novel for pediatric
T1D interventions and may be easily scalable if the trial results
confirm efficacy. We plan to disseminate the results of this trial
to the pediatric diabetes community and broader medical
community through national and international presentations at
relevant scientific meetings and peer-reviewed manuscripts.
We believe that there will be greater use of telehealth to deliver
behavioral treatments for families of youth with T1D in the
future because of the increasing adoption of telemedicine parity
laws across the United States [57] and increased affinity for
technology-enabled solutions to common needs in younger
generations [58], including the need for convenient health care
access [59]. We believe the format and general content of
REDCHiP may be amenable to caregivers of older youth with
T1D who also struggle with fear of hypoglycemia. Last, we
expect that REDCHiP is in line with initiatives from the National
Institute of Diabetes and Digestive and Kidney Diseases, which
call for the development of more family-centered, efficacious,
cost-effective, and easily scalable behavioral health interventions
[60].

Participants
For this randomized clinical trial, we will recruit 180 families
of young children with T1D. Inclusion criteria are child aged
from 2 to 5.99 years, T1D diagnosis ≥6 months, and use of an
intensive insulin regimen (eg, insulin pump or multiple daily
injections). Exclusion criteria are caregivers of children on a
conventional insulin regimen, children who have an allergy or
sensitivity to the adhesive and/or skin preparation used for a
CGM, children with a comorbid chronic condition (eg, renal
disease), and caregivers who do not speak English.
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Recruitment
We will recruit into the study at least one caregiver (mother,
father, or guardian) who is primarily involved in the child’s
daily T1D management. Each site will apply standardized
recruitment procedures approved by a single IRB to achieve the
target sample. We will use a combination of in-clinic and
telephone recruitment. Families who express interest in
participating via telephone will complete IRB-approved
telephone informed consent procedures including an approved
eConsent developed in the Research Electronic Data Capture
(REDCap) system [61,62]. Families recruited in person may
complete an eConsent or standard paper consent.

Randomization
This study will use a 2-arm randomized attention control design
with 90 families recruited to each of the REDCHiP and attention
control intervention conditions. We will stratify caregivers based
on their child’s sex, child age (2 to 3 years versus 4 to 5 years)
and CGM use (CGM or no CGM) and randomize to condition
using blocks of eight. Recruitment and randomization will occur
simultaneously across all participating sites using site-specific
randomization envelopes prepared by the study biostatistician.
This strategy will allow us to populate groups using caregivers
from any site, thereby improving our recruitment efficiency and
minimizing possible clinic effects.

Study Visit Procedures
After informed consent and randomization, all families will
complete study visit 1, during which caregivers will complete
online surveys in REDCap and we will show caregivers (via a
short video) how to place the research-grade accelerometer on
their child’s nondominant wrist (to measure child physical
activity) or ankle (to measure child sleep) and how to place the
accelerometer on their own nondominant wrist to measure
caregiver sleep. We will also teach caregivers how to upload
glucometer and insulin pump data from home to a central study
database using a commercially available data aggregating system
(Glooko). In cases where caregivers cannot use the data

Patton et al
aggregating system because of problems with device
compatibility, we will collect .csv files. To measure children’s
daily glucose levels, we will place a FreeStyle Libre Pro (Abbott
Laboratories) CGM sensor on the child’s upper nondominant
arm. We will collect a finger stick blood sample from children
using a reliable mail-in kit to measure a baseline HbA1c level.
Finally, we will determine if caregivers need to borrow any
equipment to participate in the intervention (eg, web camera,
microphone, or tablet). After study visit 1, caregivers will begin
participating in video-based telehealth sessions according to
their group assignment (eg, REDCHiP or attention control
intervention). Caregivers will participate in 10 video-based
telehealth sessions administered during 13 weeks via a
HIPAA-compliant telehealth platform that permits
multiparticipant video teleconferencing so that each caregiver
can both see and hear other caregivers. During weeks 14 to 15
of the trial, all families will engage in study visit 2 to complete
posttreatment surveys online, collect accelerometry data from
children and caregivers, collect child CGM data and finger stick
blood sample to measure child HbA1c, and recover any loaned
study-related devices. Approximately 12 weeks after study visit
2, all families will complete study visit 3, which will involve
final data collection: online surveys, child CGM data, and a
finger stick blood sample to measure child HbA1c (Figure 2 and
Table 3).
Of note, the study protocol will enable families to complete
study visits either in their home, at the diabetes clinic, or at
another location (eg, library). Additionally, our protocol includes
strategies to retain families in the study in the rare event that
they move away (eg, telehealth, online surveys, mail-in HbA1c
kits) or recruit families who self-refer based on word of mouth
or ClinicalTrials.gov. All participating caregivers and children
will receive compensation for study visits 1 through 3. As
needed, the study will use prepaid postage boxes for families
to return study-related devices (eg, accelerometers and CGM
sensors) to further reduce the burden on participating families.

Figure 2. Participant timeline.
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Table 3. Study outcome measures.
Outcome

Measure

Assessment
schedule

Child
T1Da treatment and
history

Collect demographics; caregivers complete T1D History Questionnaire including caregiver report Visit 1

Child physical activity

Calculate daily moderate to vigorous physical activity and sedentary time based on age-specific Visits 1, 2
cutoffs using accelerometer data

Sleep

Calculate TSTc, sleep latency, and sleep efficiency (TST/total time in bed); caregivers complete Visits 1, 2
online sleep log to verify child sleep versus periods of wakeful inactivity

Glycemic control

Collect children’s blood samples using a finger stick capillary sampling kit (with or without mail- Visits 1, 2, 3
back box) developed at one of the study sites and record hemoglobin A1c; we will send samples

of family/child demographics, child insulin regimen, CGMb use, and history of T1D complications

to a central laboratory for processing using an automated G8 Analyzerd with a reference range
of 4.0% to 6.0%; this method has demonstrated reliability with a correlation of 0.98 relative to
fresh venous samples
Glucose variability

Calculate percentage above, below, and within target range (target: 70 to 180 mg/dL) and mean Visits 1, 2, 3
and standard deviation of daily glucose using FreeStyle Libre Proe data

Child treatment engage- Calculate frequency of self-monitoring blood glucose and mealtime (bolus) insulin use [63] using Visits 1, 2, 3
ment
device data (eg, glucometer and insulin pump)
Caregiver
Hypoglycemia fear

Calculate total, worry, and behaviors scores from the HFS-PYCf [15,26]

Visits 1, 2, 3

Parenting stress

Calculate stress frequency and stress difficulty scores from the PIPg [64]

Visits 1, 2, 3

Depressive symptoms

Calculate total score from the CES-D-Rh [65]

Visits 1, 2, 3

Anxiety

Calculate total score from PROMIS-Ai [66]

Visits 1, 2, 3

Psychopathology

Calculate the depression, anxiety, and somatization scores and the Global Severity Index from

Visits 1, 2, 3

the BSI-18j [67]
Sleep

Calculate TST, sleep latency, and sleep efficiency (TST/total time in bed) using accelerometer
k

data; caregivers will also complete an online sleep log and the PROMIS-S [68], and we will
calculate total score
Treatment satisfaction
a

Calculate total score from the Treatment Satisfaction Questionnaire

Visits 1, 2 (Visits 1,
2, 3 for PROMIS-S)

Visit 2

T1D: type 1 diabetes mellitus.

b

CGM: continuous glucose monitor.

c

TST: total sleep time.

d

G8 analyzer: G8a High-Performance Liquid Chromatography Hemoglobin A1c Analyzer (Tosoh Bioscience Inc).

e

FreeStyle Libre Pro: FreeStyle Libre Pro Flash Glucose Monitoring System (Abbott Laboratories).

f

HFS-PYC: Hypoglycemia Fear Survey–Parents of Young Children.

g

PIP: Pediatric Inventory for Parents.

h

CES-D-R: Center for Epidemiological Studies–Depression Scale Revised.

i

PROMIS-A: Patient-Reported Outcomes Measurement Information System–Anxiety short form.

j

BSI-18: Brief Symptom Inventory–18.

k

PROMIS-S: PROMIS Sleep Disturbance and Sleep-Related Impairment.

Data Analysis Plan
We will measure parenting stress and caregiver fear of
hypoglycemia using the Pediatric Inventory for Parents [64]
and the Hypoglycemia Fear Survey–Parents of Young Children
[15,26], respectively. We will use child HbA1c levels and
percentage of time in range (eg, 70 to 180 mg/dL) to examine
child glycemic control and glycemic variability, respectively.
To test for treatment outcomes, we will model study visit 2
http://www.researchprotocols.org/2020/8/e17877/

XSL• FO
RenderX

scores as a function of visit 1 scores, condition (REDCHiP
versus attention control intervention), and selected covariates
(eg, race/ethnicity, pump use) in mixed models that include a
random intercept to account for clustering of participants within
group cohorts. We will accommodate nonnormal outcome
variables with log transformation, modeling with an appropriate
generalized mixed model or nonparametric test. We will test
the effect of condition based on whether the 95% confidence
interval for the condition coefficient includes zero (equivalent
JMIR Res Protoc 2020 | vol. 9 | iss. 8 | e17877 | p. 6
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to a 2-sided test at α=.05). To determine long-term treatment
effects, we will test for sustained improvement on outcome
variables by modeling scores at study visit 3 as a function of
visit 1 scores and condition (REDCHiP versus attention control
intervention). To control the overall rate of type I errors, we
will conduct these analyses only for variables with a statistically
significant condition effect in our primary analysis of treatment
outcomes.

Power Analysis
We anticipate recruiting 180 families, allowing for a 20%
attrition rate and resulting in a final goal of completing the trial
with at least 144 families. We assessed power using a simulation
study; each simulated dataset contained 40 clusters (20
REDCHiP, 20 attention control intervention) of 4 to 5
participants each. We simulated posttreatment scores using the
following model: Yij = rXij + ui + ES×Conditioni + εij, where
Yij is the posttreatment score for the jth participant in the ith
cluster, r is the within-cluster correlation between baseline and
posttreatment scores (set to .72 based on pilot data), Xij is the
ijth participant’s baseline score, ui is the normally distributed
random intercept for the ith cluster, ES is the standardized effect
size (set to 0.6 standard deviations based on pilot data),
Condition is an indicator (1 for REDCHiP, 0 for attention control
intervention), and ε is a normally distributed error term. The
variances of ui and εij were set to yield a within-condition
intraclass correlation coefficient of .10. We fit a mixed model
with a random cluster intercept and baseline score and condition
as predictors to each of 1000 simulated data sets. To compute
estimated power we took the average number of data sets for
which the condition was statistically significant in a 2-sided test
at α=.05. Based on the indicated parameter values and sample
size, estimated power was 83%. For 40 groups averaging 3.6
families each, estimated power was 90%. Recognizing this trial
will include a control group, which could attenuate our
REDCHiP effect, if we conservatively reduce the standardized
effect size to 0.4 standard deviations, estimated power is 85%.

Results
Recruitment began in July 2019, and enrollment is ongoing.
The first wave of the intervention began in December 2019. We
anticipate completing enrollment in 2023. Final reporting of
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results will occur within 12 months of the primary completion
date.

Discussion
Limitations
This trial will focus on families of young children with T1D
and exclude children who are on conventional insulin therapy,
which could limit some of its generalizability. However, we
anticipate little negative impact from this decision because
intensive insulin therapy is now the gold standard regimen for
individuals with T1D. An examination of maintenance effects
of REDCHiP up to 3 months’ posttreatment will occur, but we
will not be able to draw inferences regarding longer term effects.
Our trial includes numerous outcome measures, which increases
the risk of missing data. We have attempted to reduce the risk
of missing data through device use (eg, accelerometry to
measure physical activity and sleep) and online questionnaire
access and data sharing. We intend to give caregivers free and
accessible technology support before and during telehealth visits
in order to reduce any disruptions due to difficulties with the
telehealth platform. We intend to stratify our samples according
to child sex, age, and CGM status to control for any effect of
these variables in our final models. Yet there may be other
demographic variables we will not be able to control for a priori
that moderate caregiver fear of hypoglycemia, and we may need
to adjust for those in our final analyses. In addition, we intend
to identify whether young children are using a hybrid closed
loop or predictive low-glucose management system via caregiver
report or electronic health record review and may adjust for
these variables in our final analyses.

Conclusions
Our experience studying fear of hypoglycemia in families of
young children with T1D reveals that this is a common fear for
caregivers that is related to poorer quality of life and suboptimal
child glycemic control. Our initial pilot study revealed promising
effects for using cognitive behavioral techniques and a
group-based telehealth approach to reduce caregiver fear of
hypoglycemia. If this larger, multisite trial confirms the efficacy
of REDCHiP and the acceptability and feasibility of our
telehealth delivery method, future directions will focus on
widespread dissemination of the REDCHiP intervention and
implementation across a variety of clinic settings.
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